Oocyte Cryopreservation: Slow Cooling Versus Vitrification Techniques on Oocyte Survival

This study has been completed.
Sponsor:
Collaborator:
EMD Serono
Information provided by (Responsible Party):
Claudio Benadiva, University of Connecticut Health Center
ClinicalTrials.gov Identifier:
NCT00602966
First received: January 15, 2008
Last updated: October 26, 2011
Last verified: October 2011

January 15, 2008
October 26, 2011
July 2006
October 2009   (final data collection date for primary outcome measure)
Oocyte survival [ Time Frame: When patient returns for thaw cycle ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00602966 on ClinicalTrials.gov Archive Site
Implantation rate [ Time Frame: 2 weeks after transfer of thawed oocyte ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Oocyte Cryopreservation: Slow Cooling Versus Vitrification Techniques on Oocyte Survival
Oocyte Cryopreservation: Comparison of Slow Cooling Versus Vitrification Techniques on Oocyte Survival, Fertilization, and Embryo Development

Oocyte cryopreservation has been studied for many years without much success in refining a method that has consistent, reliable results in producing viable embryos and clinical pregnancies. In 1986 the first baby was born from an embryo created from a frozen oocyte; however, since then there have been less than 150 births from frozen eggs. To date, there are no reportable adverse outcomes in the children born from frozen oocytes. The research continues to look at different methods of oocyte cryopreservation. Many smaller studies have been conducted with some success but larger clinical trials are needed to replicate these findings. The conventional cryopreservation technique has been slow cooling with differing methods of freezing; however, vitrification is now being researched as the potential cryopreserving method that holds some promise for the future.

Our hypothesis is the use of vitrification (quick freezing) to cryopreserve oocytes in patients undergoing in-vitro fertilization will be more successful than slow freezing in oocyte survival, fertilization rate with ICSI and subsequent embryo development, implantation rate and pregnancy rate.

Cryopreservation of oocytes is desirable because it: 1) would allow infertility patients to store excess oocytes instead of embryos, eliminating some of the ethical and religious concerns that accompany embryo storage; 2) permit storage of donor oocytes to avoid donor-recipient synchronization difficulties; and 3) can help women who may face sterilization due to chemotherapy or radiation. Oocyte cryopreservation is therefore gaining in popularity as an option for infertility treatment as well as fertility preservation.

Oocyte cryopreservation using conventional slow-cooling methods has not had much success; however more recent results have provided more optimism (Boldt et al., 2003; Porcu et al., 1997; 2000; 2002; Yang et al., 1998; 1999; 2002; Winslow et al., 2001). Vitrification has also been employed (Hong et al., 1999; Kuleshova et al., 1999; Yoon et al., 2000, 2003; Chung et al 2000; Wu et al., 2001: Kuwayama et al., 2005) with increased oocyte survival rate and live births. Vitrification is performed by suspending the oocytes in a solution containing a high concentration of cryoprotectants and then plunging them directly into liquid nitrogen (Rall and Fahy, 1985). The advantage of this technique is to prevent the formation of ice crystals within the oocyte. However the toxic effect of the high concentration of the cryoprotectant media has been a concern. New vitrification techniques which attempt to accelerate the cooling rate by decreasing the cryosolution volume and concentration, may reduce the potential toxicity. In addition, a more rapid cooling rate results in reduced chilling injury (Vajta et al., 1998).

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

The Center for Advanced Reproductive Services patient population

Infertility
Not Provided
  • Slow Freeze
  • Vitrification

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
14
May 2010
October 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients ≤ 36 years old
  • Day #3 follicle stimulation hormone (FSH) < 10mIU/ml, and Estradiol < 70 pg/ml.
  • The study will be limited to couples who do not wish to cryopreserve excess embryos, who would otherwise have their excess oocytes discarded.
  • Body Mass Index (BMI) ≤ 35
  • Patients currently being seen in our offices

Exclusion Criteria:

  • Male partner requiring microsurgical epididymal sperm aspiration or testicular sperm extraction (MESA/TESE) for sperm retrieval
  • Day #3 follicle stimulation hormone (FSH) > 10mIU/ml, or estradiol > 70 pg/ml
  • Diagnosis of Polycystic Ovary Syndrome (PCOS)
  • Body Mass Index (BMI) >35
Female
21 Years to 36 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00602966
06-336-2, 26525
No
Claudio Benadiva, University of Connecticut Health Center
University of Connecticut Health Center
EMD Serono
Principal Investigator: Claudio Benadiva, MD, HCLD The Center for Advanced Reproductive Services, P.C.
University of Connecticut Health Center
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP